Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FOLFIRINOX for advanced biliary tract cancer
jRCTs031180082Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FOLFIRINOX in biliary cancer, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Progression-free survival. Started Jun 2016; status: completed.
02
Drugs
FOLFIRINOX
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCTs031180082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180082.